RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
RedHill Biopharma (RDHL) Tops Q3 EPS by 41c
November 19, 2019 7:05 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of $0.03, $0.41 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.77 million.
Financial highlights for the quarter ended September 30, 2019:
Net Revenues of $1.4 million in the third quarter of 2019, compared to $1.6 million in the second quarter of 2019. Gross Profit of $0.8 million in the third quarter of 2019, compared to $1.1 million in the second quarter of 2019. Research and Development Expenses of $2.8 million in the third quarter of 2019, compared to $7.0 million in the second quarter of 2019.... More